Biomarker based identification of aggressive prostate cancer in blood and urine samples


Session type:


Lina Maria Carmona Echeverria1,Thomas Johnson2,Matthew Eldridge3,Sarah Vowler3,Anne George2,Marie Corcoran2,Johannah Burge2,Sara Stearn2,David Neal2,Hayley Pye4,Susan Heavey4,Hayley Whitaker4
1University College London,2Uro-oncology Group, Cambridge University,3Bioinformatics Core Facility, CRUK Cambridge Institute,4Division of urgery and Interventional Science, University College London



Current diagnostic tests for prostate cancer provide limited prognostic and diagnostic information and therefore many patients undergo unnecessary biopsies and medical treatment. Current tests are unable to distinguish which men will develop aggressive cancer without the need for a biopsy. Identifying new fluidic biomarkers will allow us to selectively treat those whose disease could be life-limiting, and spare those who are more like to die with their disease rather than of it.


A panel of mRNA biomarkers that can discriminate between early stage and metastatic disease have been identified in tissue from human prostate cancer patients. We have performed fluidigm analysis in PAXgene blood samples from a group of patients with different stages of prostate cancer. Urine analysis on the same patients using qPCR has been performed to develop a new minimally invasive biomarker test.


Based on the PAXgene results and in combination with immunohistochemistry, survival data, androgen regulation and statistical significance, 20 genes have been selected from the initial panel. Urinary RNA has been successfully amplified and qPCR data validating the biomarker panel in these samples will be presented in correlation with clinical data.


A minority of prostate cancers are aggressive, and these cases must be identified early in order to best manage the disease. A minimally invasive fluidic based biomarker test to identify these cases would represent a useful addition to the clinical management of prostate cancer.